β-Elemene inhibits the proliferation of esophageal squamous cell carcinoma by regulating long noncoding RNA-mediated inhibition of hTERT expression

Anti-Cancer Drugs

Volumn 26, Issue 5, 2014, Pages 531-539

  Hu, Zhaoyang ^a   Wu, Hongjin ^a   Li, Ying ^a   Hou, Qiang ^a   Wang, Yan ^a   Li, Shuang ^a   Xia, Bing ^a   Wu, Shixiu ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

esophageal carcinoma; human telomerase reverse transcriptase; long noncoding RNA; proliferation; elemene

Indexed keywords

ANTINEOPLASTIC AGENT; BETA-ELEMENE; LONG UNTRANSLATED RNA; SESQUITERPENE; TELOMERASE;

CELL PROLIFERATION; DRUG EFFECTS; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION; HUMANS; RNA, LONG NONCODING; SESQUITERPENES; TELOMERASE;

EID: 84939970408     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000216     Document Type: Article

References (43)

1. Stewart BW, Wild C. World cancer report 2014. IARC Publications: Lyon; 2014.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2095-128.
3. Parkin DM, Bray F. Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness. Eur J Cancer 2009; 45:756-764.
4. Pandeya N, Olsen CM, Whiteman DC. Sex differences in the proportion of esophageal squamous cell carcinoma cases attributable to tobacco smoking and alcohol consumption. Cancer Epidemiol 2013; 37:579-584.
5. Higuchi K, Koizumi W, Tanabe S, Sasaki T, Katada C, Azuma M, et al. Current management of esophageal squamous-cell carcinoma in Japan and other countries. Gastrointest Cancer Res 2009; 3:153-161.
6. Vega KJ, Jamal MM. Changing pattern of esophageal cancer incidence in New Mexico. Am J Gastroenterol 2000; 95:2352-2356.
7. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. The Lancet 2013; 381:400-412.
8. Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer 2011; 10:38.
9. Yang QQ, Deng YF. Long non-coding RNAs as novel biomarkers and therapeutic targets in head and neck cancers. Int J Clin Exp Pathol 2014; 7:1286-1292.
10. Gibb EA, Vucic EA, Enfield KS, Stewart GL, Lonergan KM, Kennett JY, et al. Human cancer long non-coding RNA transcriptomes. PLoS One 2011; 6: e25915.
11. Chen FJ, Sun M, Li SQ, Wu QQ, Ji L, Liu ZL, et al. Upregulation of the long non-coding RNA HOTAIR promotes esophageal squamous cell carcinoma metastasis and poor prognosis. Mol Carcinog 2013; 52:908-915.
12. Smith LL, Coller HA, Roberts JM. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol 2003; 5:474-479.
13. Cao Y, Li H, Deb S, Liu JP. TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene 2002; 21:3130-3138.
14. Horikawa I, Barrett JC. Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 2003; 24:1167-1176.
15. Masutomi K, Yu EY, Khurts S, Ben-Porath I, Currier JL, Metz GB, et al. Telomerase maintains telomere structure in normal human cells. Cell 2003; 114:241-253.
16. Zhu T, Xu Y, Dong B, Zhang J, Wei Z, Xu Y, et al. ?-Elemene inhibits proliferation of human glioblastoma cells through the activation of glia maturation factor ? and induces sensitization to cisplatin. Oncol Rep 2011; 26:405-413.
17. Li QQ, Wang G, Huang F, Banda M, Reed E. Antineoplastic effect of betaelemene on prostate cancer cells and other types of solid tumour cells. J Pharm Pharmacol 2010; 62:1018-1027.
18. Zhu T-Z, Li X-M, Luo L-H, Xu Y-H, Cao P, Liu Y, et al. ?-Elemene inhibits proliferation through crosstalk between glia maturation factor ? and extracellular signal-regulated kinase 1/2 and impairs drug resistance to temozolomide in glioblastoma cells. Mol Med Rep 2014; 10:1122-1128.
19. Congrains A, Kamide K, Katsuya T, Yasuda O, Oguro R, Yamamoto K, et al. CVD-Associated non-coding RNA, ANRIL, modulates expression of atherogenic pathways in VSMC. Biochem Biophys Res Commun 2012; 419:612-616.
20. Yang Y, Li H, Hou S, Hu B, Liu J, Wang J. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in nonsmall-cell lung cancer cell. PLoS One 2013; 8:e65309.
21. Burdon KP, Macgregor S, Hewitt AW, Sharma S, Chidlow G, Mills RA, et al. Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1. Nat Genet 2011; 43:574-578.
22. Xu L, Tao S, Wang X, Yu Z, Wang M, Chen D, et al. The synthesis and antiproliferative effects of beta-elemene derivatives with mTOR inhibition activity. Bioorg Med Chem 2006; 14:5351-5356.
23. Zhu T, Zhao Y, Zhang J, Li L, Zou L, Yao Y, Xu Y. ?-Elemene inhibits proliferation of human glioblastoma cells and causes cell-cycle G0/G1 arrest via mutually compensatory activation of MKK3 and MKK6. Int J Oncol 2011; 38:419-426.
24. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discov 2011; 1:391-407.
25. Lau E. Non-coding RNA: zooming in on lncRNA functions. Nat Rev Genet 2014; 15:574-575.
26. Wang CM,Wu QQ, Li SQ, Chen FJ, Tuo L, Xie HW, et al. Upregulation of the long non-coding RNA PlncRNA-1 promotes esophageal squamous carcinoma cell proliferation and correlates with advanced clinical stage. Dig Dis Sci 2014; 59:591-597.
27. Li J, Chen Z, Tian L, Zhou C, He MY, Gao Y, et al. LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. Gut 2014; 63:1700-1710.
28. Xie HW, Wu QQ, Zhu B, Chen FJ, Ji L, Li SQ, et al. Long noncoding RNA SPRY4-IT1 is upregulated in esophageal squamous cell carcinoma and associated with poor prognosis. Tumour Biol 2014; 35:7743-7754.
29. Visel A, Zhu Y, May D, Afzal V, Gong E, Attanasio C, et al. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature 2010; 464:409-412.
30. Burdon KP, Crawford A, Casson RJ, Hewitt AW, Landers J, Danoy P, et al. Glaucoma risk alleles at CDKN2B-AS1 are associated with lower intraocular pressure, normal-tension glaucoma, and advanced glaucoma. Ophthalmology 2012; 119:1539-1545.
31. Yap KL, Li S, Muñoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 2010; 38:662-674.
32. Bilguvar K, Yasuno K, Niemelä M, Ruigrok YM, von Und Zu Fraunberg M, van Duijn CM, et al. Susceptibility loci for intracranial aneurysm in European and Japanese populations. Nat Genet 2008; 40:1472-1477.
33. Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD, et al. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet 2011; 43:621-629.
34. Calado R, Young N. Telomeres in disease. F1000 Med Rep 2012; 4:8.
35. Cech TR, Nakamura TM, Lingner J. Telomerase is a true reverse transcriptase. A review. Biochemistry (Mosc) 1997; 62:1202-1205.
36. Marconett CN, Sundar SN, Tseng M, Tin AS, Tran KQ, Mahuron KM, et al. Indole-3-carbinol downregulation of telomerase gene expression requires the inhibition of estrogen receptor-Alpha and Sp1 transcription factor interactions within the hTERT promoter and mediates the G1 cell cycle arrest of human breast cancer cells. Carcinogenesis 2011; 32:1315-1323.
37. Saretzki G, Ludwig A, von Zglinicki T, Runnebaum IB. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther 2001; 8:827-834.
38. Kraemer K, Fuessel S, Schmidt U, Kotzsch M, Schwenzer B, Wirth MP, Meye A. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res 2003; 9 (Pt 1): 3794-3800.
39. Kanaya T, Kyo S, Hamada K, Takakura M, Kitagawa Y, Harada H, Inoue M. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin Cancer Res 2000; 6:1239-1247.
40. Xu D, Gruber A, Björkholm M, Peterson C, Pisa P. Suppression of telomerase reverse transcriptase (hTERT) expression in differentiated HL-60 cells: regulatory mechanisms. Br J Cancer 1999; 80:1156-1161.
41. Pasmant E, Sabbagh A, Vidaud M, Biéche I. ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J 2011; 25:444-448.
42. Li WQ, Pfeiffer RM, Hyland PL, Shi J, Gu F, Wang Z, et al. Genetic polymorphisms in the 9p21 region associated with risk of multiple cancers. Carcinogenesis 2014; 35:2698-2705.
43. de Kok JB, Ruers TJ, van Muijen GN, van Bokhoven A, Willems HL, Swinkels DW. Real-time quantification of human telomerase reverse transcriptase mRNA in tumors and healthy tissues. Clin Chem 2000; 46:313-318.